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Abstract 
Background: Some published studies reported beneficial effects of the Mediterranean Diet (MedDiet) on 
cognitive function in an aging population. But evidence from a limited number of randomized controlled 
trials (RCTs) is scarce and inconsistent. It is not clear whether a MedDiet offers benefits in maintaining 
cognitive function or in preventing cognitive decline in the older adult. 
Methods: An exhaustive search of online medical literature was performed using MEDLINE-PubMed, Web 
of Science, and CINAHL-EBSCO. Keywords used included: Mediterranean Diet, cognition, cognitive 
function decline, and older adult population. Articles that assessed cognitive function through RCTs in an 
aging population on the Mediterranean diet were selected. The quality of relevant articles was evaluated 
using the GRADE guidelines. 
Results: Nine articles were reviewed for relevancy and 3 studies that were RCTs and met eligibility criteria 
were chosen for analysis. The first study was done on a group of an older Mediterranean population with 
cardiovascular (CV) risk factors. It was not originally designed to do a cognitive function assessment, 
which was done at the end using two screening tests. The second study was a post hoc analysis of the 
first study and used a comprehensive battery of neurophysiological tests to analyze cognitive function. 
Both of the above studies found that a long-term adherence to the Mediterranean diet was associated 
with an improved cognitive function. The third study was done on a healthy Australian population staying 
on the MedDiet for a short period of time. No significant statistical differences in cognitive functioning 
were detected in healthy older adults. The overall quality of the studies is low to moderate based on 
Grade guidelines. 
Conclusion: Studies investigating the MedDiet as a prevention of cognitive decline due to aging fail to 
provide strong evidence of its beneficial effect. Further research with larger study samples and longer 
periods of time is necessary to produce a better quality of evidence regarding a benefit of MedDiet in an 
aging population. 
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Abstract   
 
Background: Some published studies reported beneficial effects of the Mediterranean Diet 
(MedDiet) on cognitive function in an aging population. But evidence from a limited number of 
randomized controlled trials (RCTs) is scarce and inconsistent.  It is not clear whether a MedDiet 
offers benefits in maintaining cognitive function or in preventing cognitive decline in the older 
adult. 
 
Methods:  An exhaustive search of online medical literature was performed using 
MEDLINE-PubMed, Web of Science, and CINAHL-EBSCO. Keywords used included:  
Mediterranean Diet, cognition, cognitive function decline, and older adult population. Articles 
that assessed cognitive function through RCTs in an aging population on the Mediterranean diet 
were selected. The quality of relevant articles was evaluated using the GRADE guidelines. 
 
Results:   
Nine articles were reviewed for relevancy and 3 studies that were RCTs and met eligibility 
criteria were chosen for analysis. The first study was done on a group of an older Mediterranean 
population with cardiovascular (CV) risk factors. It was not originally designed to do a cognitive 
function assessment, which was done at the end using two screening tests. The second study was 
a post hoc analysis of the first study and used a comprehensive battery of neurophysiological 
tests to analyze cognitive function. Both of the above studies found that a long-term adherence to 
the Mediterranean diet was associated with an improved cognitive function. The third study was 
done on a healthy Australian population staying on the MedDiet for a short period of time. No 
significant statistical differences in cognitive functioning were detected in healthy older adults. 
The overall quality of the studies is low to moderate based on Grade guidelines. 
 
Conclusion:   
Studies investigating the MedDiet as a prevention of cognitive decline due to aging fail to 
provide strong evidence of its beneficial effect. Further research with larger study samples and 
longer periods of time is necessary to produce a better quality of evidence regarding a benefit of 
MedDiet in an aging population. 
 
Keywords:  Mediterranean diet, cognition, cognitive function decline, older adult 
population. 
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 Mediterranean Diet and Age-Related Cognitive Decline  
BACKGROUND 
 
According to the World Health Organization (WHO), at present, there are about 47 
million people worldwide living with dementia, with 9.9 million new cases developing 
annually.1 Dementia is a gradual, progressive disease that predominantly develops in older 
populations, although, it is not a part of a normal aging process.2 It affects many aspects of an 
individual’s life including memory and thinking, judgment and behavior, the ability to learn, the 
use of language, and independent executive functioning. Initially, dementia is exhibited as 
forgetfulness and mild cognitive impairment (MCI), but eventually it leads to severe debilitation 
requiring continuous, around-the-clock assistance. Individuals afflicted by dementia become 
disoriented in time and place, not able to recognize their family members or carry on with daily 
activities. Dementia is a leading cause of disability among aging populations and it takes heavy 
physical, emotional, and financial tolls on individuals, their families, and a society.1 
Currently, there is no known effective treatment of dementia, and it is important to 
identify effective measures that can prevent cognitive decline or delay a progression of 
pathological processes leading to dementia. Numerous epidemiologic studies2-4 presented 
evidence that modifiable factors such as an active life style, weight reduction, smoking cessation, 
better education, and a healthy diet may play a role in delaying dementia by reducing vascular 
pathology and neurodegeneration. There is a considerable amount of evidence4-7 supporting a 
notion that dietary habits, particularly a Mediterranean Diet (MedDiet), can slow down age-
related cognitive decline and possibly delay onset of dementia. In addition, numerous 
publications5,8-11 present data that a MedDiet is associated with overall decrease in mortality, 
incidence of cardiovascular diseases (CVDs), neoplastic processes, diabetes, and obesity. 
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 Health benefits of the Mediterranean Diet can probably be contributed to its components 
with high content of antioxidants and anti-inflammatory substances such as flavonoids, 
carotenoids, omega-3 and -6 polyunsaturated fatty acids, vitamins E and B.12,15 Specifically, 
extra virgin olive oil (EVOO) and mixed nuts are reach in phenolic compounds, 
monounsaturated fats (MUFA), and alpha-linolenic acid, all of which can counteract oxidative 
stress leading to neurodegeneration in the brain.15-18 Consumption of the MedDiet is associated 
with a beneficial effect to Alzheimer and Parkinson’s diseases.13,19 Reduced deposition of 
amyloid and Tau proteins was detected in the brains of patients after 9 years on a MedDiet.3 
Also, according to Pelletier et al19  who conducted magnetic resonance imaging study on older 
individual, a MedDiet may preserve white matter microstructure and benefit brain connectivity. 
Another proposed mechanism of a beneficial effect of a MedDiet is a reduction of vascular 
pathology that is common in older age. Normal decline of cognitive function due to aging can be 
accelerated by a presence of cardiovascular risk factors (CVDFs), which are linked to an early 
onset of MCI and dementia.20,21 
 Although, many epidemiologic population studies7,13 point to beneficial effects of the 
MedDiet on cognitive function, their results are inconsistent and heterogeneous in quality. As 
previously mentioned, some studies9,10,18,19 found a positive association between the MedDiet 
and cognitive function, yet others failed to demonstrate its beneficial effect.22,23 Specifically, 
neither the French Study22 on middle-age adults nor the Women’s Health study23 on healthy 
female professionals found association between a MedDiet and cognitive performance. 
 The goal of this systemic review is to clarify whether a Mediterranean diet has a 
beneficial effect on cognitive function based on data analysis of three randomized controlled 
trials (RCTs)15,25,26 available at this time.  
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METHODS 
An exhaustive online search of medical literature was performed in May 2017 using 
MEDLINE-PubMed, Web of Science, and CINAHL-EBSCO databases. The keywords used 
during this search were Mediterranean Diet, cognition, cognitive function decline, and older 
adult population. The search criteria were narrowed to randomized control trials, articles 
published within past 5 years, studies on human subjects, and English language publications. 
The articles that assessed cognitive functions in a group of older aging populations on the 
MedDiet were included. References of the included studies and other relevant articles were 
examined for further sources. Applicable articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE) working group 
guidelines.24 
RESULTS  
The initial search of the medical literature using above-named keywords yielded 54 
articles. After screening abstracts and titles for eligibility, a total of 3 articles that met inclusion 
criteria were chosen for a review.15,25,26 One of the included articles15 was located by using the 
name of the trial and the first author’s name that were obtained from the published protocol, 
which was present in the initial search result.27 The quality of evidence presented in the articles 
was evaluated using GRADE guidelines (see Table I), and a summary of the 3 studies and their 
difference can be seen in Table II. 
All of the included articles were randomized control trials. Two of the 3 chosen 
studies25,26 examined an effect of the MedDiet supplemented with either olive oil or nuts in a 
group of Mediterranean aging population with increased risk of CV disease. The Valls-Pedret et 
al study26 was a post hoc study of the Martinez-Lapiscina et al study,25 which didn't have a 
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baseline measurement of cognitive function. The Valls-Pedret et al study26 performed cognitive 
functions measurements in a greater extent at the beginning and the end of the trial. Both of these 
long-term studies25,26 found a statistically significant difference in various aspects of cognitive 
function (see Table III and IV). The third study15 was done on an Australian aging population, 
which were physically and cognitively healthy. This study used an extensive battery of the 
neurophysiological tests for a cognitive functions assessment and found no evidence of cognition 
improvement in elderly healthy adults after 6 months of being on a MedDiet (See Table V).  
The PREDIMED-NAVARRA, Martinez-Lapiscina et al (2013) 
The PREDIMED parallel-group randomized controlled trial28 was originally designed to 
investigate the effects of a MedDiet on the prevention of cardiovascular disease (CVD) in 
comparison with a low-fat diet among an older Mediterranean population. The PREDIMED-
NAVARRA study25 used a subsample from the PREDIMED trial28 to assess the effect of the 
MedDiet on cognitive functions after a mean 6.5 years of follow up. The primary outcome of this 
study was cognitive performance scores on two global screening tests for dementia, the Mini 
Mental State Examination (MMSE) and a Spanish version of the Clock Drawing Test (CDT).25 
All participants were screened and recruited by blinded general practitioners in the 
primary care practice setting. Study participants of a mean age of 74.6 + 5.7 years were a 
community dwelling population at a high CV risk. High CV risk was due to the presence of type-
2 diabetes or at least 3 of the following: smoking, hypertension, dyslipidemia, being overweight 
or obese, or a family history of an early onset of CVD. Patients were excluded if they had a prior 
history of illiteracy, severe chronic illness, CVD, or other conditions specified in a study 
protocol.28  
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Study randomization was a computerized process that was performed after initial 
screening for eligibility. Computer-generated random-number sequence was used to assigned 
study participants, who where well balanced in their baseline characteristics, to one of the 3 
groups. This study was single-blinded due to a nature of intervention; generally, it is not feasible 
to blind study participants to their assigned diet. All investigators, including medical personal 
and researchers were blinded to a group assignment.25  
Study participants in 2 experimental groups, either Mediterranean Diet supplemented 
with Extra Virgin Olive Oil (MedDiet+EVOO) or Mediterranean Diet supplemented with Nuts 
(MedDiet+Nuts), received either 1 liter/week of EVOO or 30 g/day of mixed nuts (walnuts, 
almonds, hazelnuts). The control group was on a fat-reduced diet without energy restrictions or 
increased physical activity and received non-food gifts as compliance incentive. Participants 
were extensively educated regarding the diet during quarterly follow-up sessions and adherence 
to the diet was validated by annual questionnaires administered by a trained dietitian. A diet 
adherence was the lowest in the controlled group assigned to a low-fat diet.25 
Initially, 1055 participants were recruited for the study, 86 of them died (8.2%) during 
the mean 6.5 years of follow up. Out of 969 participants who were alive, 522 (53%) participants 
agreed and underwent neurophysiological testing over a period of 8 months at the primary care 
centers. A total number of analyzed participants was 224 in the MedDiet+EVOO group, 166 in 
the MedDiet+Nuts group, and 132 in the low-fat diet control group. A number of participants 
required for each of 3 groups was determine to be 132, which allows to detect 1 Unit mean 
difference in MMSE between experimental groups and control with 90% power. Dropout rates 
for 3 groups were 46%, which include 36% in the MedDiet+EVOO group, 52.8%, in the 
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MedDiet+Nuts group and 62.5% in the Control Group on a low-fat diet. 25 High dropout rates in 
this trial indicate a high risk of an attrition bias. 
Statistical analyses were performed on an intention-to-treat principle and general linear 
models were used to make an adjustment for possible confounding factors including sex, age, 
education, dyslipidemia, diabetes, and body mass index, and physical activity among others. 
Quantitative data for experimental groups were reported as multivariable-adjusted mean scores 
of cognitive function and compared with control at the 95% confidence interval (CI) and the p –
value of <0.05.25  
After 6.5 years of follow up the unadjusted mean MMSE and CDT scores were 
significantly higher for participants in the MedDiet+ EVOO group, but was not significantly 
different in the MedDiet+Nuts group in comparison with the low-fat control group. In 
multivariate regression analysis, the adjusted mean global cognitive functions scores on MMSE 
and CDT tests were significantly higher in the MedDiet+ EVOO group and higher in the 
MedDiet+Nuts group in comparison to the control group.25 See Table III for a summary of the 
results for this study. Results of the evaluation are presented in Table II.  
 
Valls-Pedret et al (2015) 
This was a post hoc single-blinded randomized controlled trial26 of the Martinez-
Lapiscina et al study25 with participation of the same 6 researchers. This parallel-group study was 
done for a period of median 4.1 years on the PREDIMED trial25 subsample of cognitively 
healthy older Mediterranean population at high CV risk. The primary study outcome was rates of 
cognitive changes, which were tested twice by the extensive neurophysiological battery at the 
beginning and the end of the trial.  The MMSE, Rey Auditory Verbal Learning Test (RAVLT), 
Animal Semantic Fluency, Digit Span subtest from the Wechsler Memory Scale, and the Color 
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Trail Tests were used to assess cognition in 3 composites that included memory, frontal, and 
global functions.26 
The study candidates were recruited at the PREDIMED center. The PERIMED study 
protocol 28 was followed and same eligibility criteria were applied in electing of the study 
participants. The exclusion criteria specific for this trial were Spanish language difficulties, mild 
cognitive impairment, and depression. A total of 447 eligible candidates were randomly assigned 
to either a Mediterranean diet supplemented with olive oil (MedDiet+EVOO diet), a 
Mediterranean diet supplemented with mixed nuts (MedDiet+Nuts), or a low-fat control diet 
groups. The randomization was done through computer-generated random-number sequence in 
blocks of 50.26  
The mean age of study participants was 66.8 years and majority of their characteristics 
were well balanced, except that the participants in the MedDiet+EVOO group were older (a 
mean of 2 years). Experimental groups received a diet advice on the intervention diet and food 
supplements during quarterly education sessions. Good adherence to an interventional diet was 
confirmed by a validated 14-item questionnaire and a measurement of changes in biomarkers 
specific to each intervention, urinary hydroxityrosil for MedDiet+EVOO and alpha-linolenic 
acid for MedDiet +Nuts. The low-fat diet control group participants had annual visits for 
duration of initial 3 years, followed by a protocol amendment requiring an adjustment of 
educational sessions to the same frequency as the experimental groups.  Participants in this group 
received non-food gifts.26 
Neurophysiological testing was performed at a baseline and towards the end of the trial 
after the median follow up of 4.1 years. The MMSE was used in the assessment of the global 
function of participants, and the RAVLT and the Wechsler Memory Scale were used in 
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assessment of the immediate and episodic memory. The animal fluency test, the Digit Span 
subset of the Wechsler Adult intelligence Scale (WAIS), and the Color Trail Test were added 
during the trial later on to assess changes in language and frontal function. These tests were done 
in a smaller number of participants (total n=96: 41, 25, and 30, respectively). The adjusted 
cognitive composites were calculated for each individual from the aforementioned tests and 
presented as mean standardized scores (mean z scores with 95% CI). The t test, analysis of 
variance (ANOVA) or x2 tests, and analysis of covariance (ANCOVA) were used to make 
adjustments for imbalances and variables. Significant differences were determined at the p < 
0.05.26 
  From the total of 447 participants, 360 underwent cognitive testing at the end of the trial.  
Follow up losses were sufficiently addressed and due to withdrawals, refusal to undergo 
retesting, illness, or death. Further, a total of 6 participants were excluded from the analysis due 
to depression. The final analysis included 334 participants in 3 groups, 122 in the MedDiet+ 
EVOO group, 112 in the MedDiet+Nuts group, and 95 in the control group. A total dropout rate 
from the trial was 25.3%, including 18.1 %, in the MedDiet+EVOO group, 28.8% in the 
MedDiet+Nuts group, and 34.5% in the control group. More losses among the control possibly 
introduced bias towards a benefit in this group.26 
According to multivariate analyses, at the end of the trial there was an improvement in 
the 2 RAVLTs scores that measure episodic declarative memory in all 3 groups, with significant 
differences for participants in the MedDiet+EVOO group. No significant improvements in any 
other cognitive tests were detected between the groups. On the composite scores, significant 
improvement in the frontal and global cognition was reported for the MedDiet+EVOO group and 
significant improvement in memory was reported for the MedDiet+Nuts group in comparison to 
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the control. It was observed that Color Trail Test 2 score deteriorated at the end of the trial in all 
participants, but to a significantly lesser degree in the MedDiet+EVOO group.26 Results of the 
tests are presented in Table II and IV. 
It is important to note that at the end of the trial higher incidence of mild cognitive 
impairment was detected in the MedDiet+EVOO group (13.4%), in comparison to the 
MedDiet+Nuts group (7.1%) and the control group (12.6%).26  
 
The MedLey study, Knight et al (2016) 
This study was a first parallel group randomized controlled trial15,27 to investigate 
association between a MedDiet and cognitive function in Non-Mediterranean healthy older 
adults without increased CV risk or other pathology. The primary outcome of this trial was age-
related cognitive function in 2 cohorts of healthy older adults (over 65 years old) that were 
randomly assigned to either a MedDiet or a Habitual Diet (HabDiet). During 6 months of this 
trial, cognitive function was assessed repeatedly at the baseline and then at 3 and 6 months.  
Comprehensive neurophysiological battery composed of 11 cognitive tests was used to assess 
non-pathological age-related changes in fluid cognition. Five primary composites of cognitive 
function assessment were: executive function, memory, speed processing, visual-special 
memory, and total age-related cognitive function. All composites were calculated as the mean of 
summed Z score of the following tests: Dodrill’s version of the Stroop Test, Initial Letter 
Fluency (ILF), Excluded Letter Fluency (ELF), and D-KEFS version of the Tower of London 
(TOL) for executive function; Rey and Schmidt’s, Rey Auditory Verbal Learning Test 
(RAVLT), Digit Span Forward (DSF), Digit Span Backward (DSB), and Letter-Number 
Sequencing (LNS) for memory; Symbol Search and Coding from Wechsler Adult Intelligence 
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Scale (WAIS-IV) for speed of processing; and The Benton Visual Retention Test (BVRT) for 
visual-special memory. Results of all 11 tests were combined to determine a score for total 
cognitive function.15 
Participants were recruited on a voluntarily basis at the Samson Institute for Health 
Research, South Australia. They were elderly Australian adults over 65 years old, proficient in 
English, and with normal cognitive function. Individuals with MCI, dementia, previous brain 
injury, stroke, CVD, malignancy, or any other diseases of major organs were excluded from the 
trial. Candidates who were trying to loose weight, taking appetite suppressants, or smoking, were 
also excluded.3 After initial screening eligible participants were randomly assigned to either an 
experimental group on the Cretan Mediterranean diet or to a control group on a Habitual diet.6,12 
Minimized randomization, which lessens potential of selection bias, was used for allocation. 
Researchers who were in charge of randomization, administration, and assessment of cognitive 
tests scores were blinded to the group assignments.15 
Study sample size was determined from the previous research27 together with power 
calculations and estimated to require 128 participants for 2 groups, with 64 in each. This sample 
size would have 80% power to detect significant changes at p<0.05. Out of initially recruited 166 
participants, 137 completed the trial and were analyzed, 70 participants in the experimental 
group and 67 participants in the control group. Participants in both groups were well balanced in 
their baseline characteristics. Cofounding factors (BMI, family history of chronic conditions, 
stress, and depressive symptoms) were recorded and appropriate adjustments were made in 
computing of study outcome. Study dropout rates were 17.6% for the MedDiet group and 17.3% 
for the HabDiet group and all well accounted for.15 
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The interventional Mediterranean Diet used in the MedLey trial was based on the Cretan 
Mediterranean Diet6 and MedDiet food pyramids12 and included EVOO, legumes, yogurt, fish, 
and mixed nuts among other ingredients. It is important to note that a MedDiet used in this trial 
wasn't supplemented with additional quantities of olive oil and nuts unlike the PREDIMED-
NAVARRA and MedLey studies.25,26 Throughout duration of the trial an experimental group 
received MedDiet food supplies and a control group received monetary gift vouchers. All study 
participants had ongoing visits with a qualified dietitian to reassure adherence to the diet. Study 
compliance was high at 92% and monitored by measuring specific serum biomarkers, urinary 
metabolites, and by food records and questionnaires. Descriptive statistics were done to record 
changes in food consumption and significant increase in intake of EVOO, legumes, nuts, and fish 
was noted in the MedDiet group.15 
Assessment of the effect of a Mediterranean Diet in comparison to a habitual control diet 
was performed on an intention to treat principle using Mixed Factorial Repeated Measures 
ANCOVA with simple main effects contrasts. Multivariable adjusted mean scores of cognitive 
function between intervention and control were reported with adjusted differences at the 95% CI 
and p-value of <0.05. Cognitive function measurements included total age related cognitive 
performance, executive functioning, speed of processing, memory, and visual special ability. In 
summary, the study did not find significant difference in cognitive function among healthy aging 
population on a MedDiet in comparison to the HabDiet after 6 months of the RCT.15 Results of 
multivariable adjusted mean differences between 2 groups are presented in Table V. 
DISCUSSION 
Dementia is a worldwide problem that is common in well-developed and low-income 
countries with increasing aging populations. It is one of the major causes of disability and 
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dependency for older adults and leads to a significant personal and financial burden on the 
patients, their families, and a society as a whole.1 Growing evidence from literature and 
numerous epidemiologic studies found association between a Mediterranean diet and cognitive 
function improvement. 9,10,18,19,30 Use of a MedDiet has been proposed as a preventive measure, 
which delay cognitive decline due to vascular or neurodegenerative pathologies.3,13,15-18 
This systematic review covers 3 available RCTs5,25,26 that investigated effects of a 
Mediterranean diet on cognitive function in older adult populations. Two of these studies25,26 
found significant differences in some aspects of cognitive performance in a sample of elderly 
adults with increased risk of CVD. Results of these studies suggest that a long-term use of a 
MedDiet is associated with improved cognitive function in older population. On contrary, the 
third, short-term study15 that investigated a MedDiet effect among healthy older adults reported 
null findings. The reviewed studies have certain limitations and provided inconsistent and 
contradictory results. Quality of the evidence from the reviewed studies was evaluated and 
considered to be low and moderate based on the GRADE guidelines.24 Grade evidence profile 
can be seen in Table I. 
 The major common limitations of the above studies15,25,26 include one-way blinding, 
possible recruitment bias, a small sample size, and high attrition bias (see Table II for 
comparison). All three studies were single-blinded due to a nature of the intervention. In general, 
it is not feasible to conduct double-blinding in this type of trial when food is used as an 
experimental intervention. Study participants were well aware of their diet, received extensive 
nutritional counseling, and had to fill out dietary questionnaires to assure adherence. Data 
collectors, researchers, and medical personal involved in these RCTs were blinded.15,25,26  
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 It is highly probable that recruitment bias was present in all reviewed studies, since study 
participants who showed interest in MedDiet were more likely to signed up for a trial. In 
addition, the Martinez-Lapiscina et al25 and Valls-Pedret et al studies26 were confined to the 
Mediterranean region and were done in a group of aging adults with high risk of CVD, while 
recruitment for the MedLey study15 was done at one center in Australia and included very 
healthy, well-educated elder adults who were eager to make valuable social contribution. Lack of 
diversity in population samples make it difficult to arrive to a conclusion regarding applicability 
of these studies to general elderly population. Some reports22,29 indicate that an effect of a 
MedDiet on a rate of cognitive decline and dementia might be determined by cultural or racial 
differences. 
All of the reviewed studies15,25,26 had a relatively small sample size and high drop out 
rates in all groups. Attrition bias was especially high in the PREDIMED-NAVARRA study26 
(average: 46%) and much less in the MedLey study15 (average: 17%). Lower drop out rate in the 
MedLey study15 was most likely due to a short duration of the trial (6 months) with frequent 
follow-ups to assure high adherence (92%). Also, the PREDIMED-NAVARRA and Valls-Pedret 
et al studies had much higher drop out rates in the control group with possible bias towards 
benefit.25,26  
Each of the reviewed studies had additional unique limitations.15,25,26 The PREDIMED-
NAVARRA longitudinal study25 was not originally intended to investigate effects of the 
MedDiet on cognition and didn't include a baseline cognitive functions assessment. Also, it was 
assumed that study participants were similar in regards to their cognition due to their similar 
basic characteristics, proper trial randomization, and proper adjustments of cofounders.25 Two 
tests, used in this study, MMSE and CDT, are designed as dementia screening tools, offer a 
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limited measure of general cognitive function and are insufficient for a comprehensive 
assessment. The Valls-Pedret et al study26 was a post hoc analysis, which was done on a subset 
of participants from the PREDIMED-NAVARRA trial.25 Although, it offered extensive 
assessment of cognitive functions through comprehensive neurophysiological battery, it had very 
wide CIs, inconsistency in testing, participation of the same 6 researchers from the Martinez-
Lapiscina et al study,26 and a conflict of interest due to partial funding by the nut companies.  
The MedLey study15 with null findings was a very short in duration, which might be not enough 
to observe a full effect of the MedDiet on cognitive functions. This study has been extended to 
18 months and its results are still unpublished.  
It is difficult to combine and compare data of these studies due to a use of different 
experimental and control groups from different regions, use of different variations of MedDiet 
and a control diet, and use of different neurophysiological tests for a cognitive functions 
assessment. 
Both, Martinez-Lapiscina et al25 and Valls-Pedret et al26 longitudinal studies found 
significant difference in cognitive performance in a group of elderly adults with increased risk of 
CVDs from the Mediterranean region while the Knight et al study15 produced null results in a 
group of very healthy, physically and mentally fit individuals from Australia. It is possible that a 
beneficial effect of MedDiet is specific to Mediterranean population and it may delay cognitive 
decline due to vascular pathology, but not due to normal aging.11,13,15,25 Based on results of these 
studies it is difficult to conclude whether a MedDiet is beneficial in maintaining cognitive 
function, in preventing cognitive decline due to aging, or in slowing down pathological 
processes. Null finding in the Knight et al study15 may indicate that benefits contributed to a 
MedDiet may be due to a synergetic effect of more active, healthy life style.13,30 
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In regards to a cognitive function assessment, results of the reviewed studies are 
inconsistent. While Martinez-Lapiscina et al25 found significant difference in cognitive 
performance on the MMSE, Valls-Pedret et al26 reported negative findings on the same test. 
Valls-Pedret et al26 reported different results of a cognitive assessment in two experimental 
groups. In multivariate analyses significant improvement in episodic declarative memory was 
detected in the MedDiet+EVOO group and on the composite scores significant improvements 
were detected in the frontal and global cognition for the MedDiet+EVOO group, and in memory 
for the MedDiet+Nuts group. Different results of cognitive performance in two experimental 
groups might indicate that individual components of the MedDiet (EVOO or Nuts) affect various 
aspects of global cognition. This view is supported by other publications suggesting that a 
beneficial effect of a MedDiet might be due to its individual components.5,6,13 The null finding in 
cognitive function improvement among healthy older adults reported by Knight et al may be due 
to a short duration of the trial on a small sample of healthy individuals with initially high level of 
cognitive function.15 
Martinez-Lapiscina et al25 and Valls-Pedret et al26 studies had two experimental groups in 
which a MedDiet was supplemented with either EVOO or mixed nuts, and used a low-fat diet as 
control; while Knight et al15 used Cretan version of a MedDiet, which contained EVOO and 
mixed nut, but not in excessive amount, a control group in is this study was on a habitual 
Western diet. The first studies reported The Knight et al15 proposed that improvements of 
cognitive function reported by Martinez-Lapiscina et al25 and Valls-Pedret et al26 might be due 
to amplified levels of EVOO and mixed nuts, that are rich in MUFA and polyphenolic 
compounds from oil an alpha-linolenic acid from nuts. 
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It will be necessary to conduct future longitudinal RCTs that are based on a standard 
definition of MedDiet,13,14 use a representative sample of aging population allowing 
generalization, reports a diet adherence based on nutrients and not food components,13 and 
employs a comprehensive neurophysiological battery offering an extensive assessment of 
cognitive function. In addition, future RCTs need to clarify which of individual components of 
MedDiet work and whether the MedDiet is beneficial in maintaining cognitive function, 
preventing cognitive decline due to aging, or in slowing down pathological processes. All the 
above questions must be addressed before making medical recommendations and changing 
practice guidelines in regards to benefits of Mediterranean diet on cognition. 
CONCLUSION 
The effect of the Mediterranean diet on cognitive function of the general aging 
population remains unclear from the 3 RCTs presented in this systematic review. Although, 
results of 2 reviewed studies indicate that the Mediterranean diet supplemented with olive oil or 
nuts might be beneficial for cognitive function in Mediterranean older adults with increased risk 
of CVDs, several limitations and inconsistent evidence preclude generalization of these results to 
average aging adults. The current evidence obtained from the only one available RCT that 
investigated an effect of a MedDiet in the healthy aging population, did not demonstrate a 
statistically significant difference in cognitive function of this group in comparison to a habitual 
diet control. To further clarify results of these findings, future RCT performed on a larger, more 
representative population samples for a longer trial duration, using a consistent choice of 
MedDiet nutrients and comprehensive neurophysiological battery are necessary. Further more, it 
is important to clarify whether a MedDiet is effective in prevention of cognitive decline due to 
normal aging or dementia development due vascular and neurodegenerative pathologies.  
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Tables 
 
Table I: GRADE Evidence Profile of Reviewed Articles  
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Martinez-
Lapiscina et al25 
RCT Not Serious  Seriousa Not Serious Seriousb Unlikely  Low 
Valls-Pedres et 
al26 
RCT Not Serious Not Serious Not Serious  
 
Seriousb 
 
Likelyc  Low 
MedLey Study by 
Knight et al15,27 
RCT Seriousd Not Serious Not Serious Not Serious Unlikely  Moderate 
a The Martinez-Lapiscina et al study didn't have a baseline cognitive functions measurements (CF wasn't  planned to be a primary 
outcome) and cognitive functions were assessed by 2 tests vs. comprehensive battery 
b High attrition rates 
c The Valls-Pedres et al study was partially funded by the Nuts Commission. Six authors of this study were also involved in the 
Martinez-Lapiscina et al study 
d The MedLey Study by Knight et al had a short duration (6 month) and investigated a different group of population making 
comparison difficult 
 
 
  
 - 27 -  
 
Table II. Summary of Differences between 3 Trials 
 Population Mean 
Age 
(years) 
Intervention  
Groups 
Control  
Group 
Duration  
(Years) 
Number of 
participants 
 
CF Assessment Attrition Rate 
(%) 
Study Outcome (statistically 
significant difference) 
Martinez-
Lapiscina 
et al 
Mediterra-
nean Older 
Adults with 
CV risk 
74.6 ± 
5.7  
2 groups: 
MedDiet + 
EVOO   
MedDiet + 
Nuts 
Low-fat diet 6.5  Total: 522  
Each Group: 
224, 166, 132 
MMSE, CDT at the 
end of the trial 
Total:  
Gr.1: 36%,  
Gr.2: 52.8%,  
Control: 62.5% 
Cognitive performance scores on 
global screening tests for dementia, 
were significantly higher than in a 
control group  
Valls-
Pedres et 
al 
Medeterra- 
nean 
Cognitively 
Healthy 
Older Adults 
with CV risk 
66.9 2 groups: 
MedDiet + 
EVOO  
MedDiet + 
Nuts 
 
 
Low-fat diet 4.1   447 
(130,112,95) 
 Baseline and at 
termination CF in 3 
composites:  
memory, frontal, global  
Tests: MMSE, RAVLT,  
Wechsler memory 
scale, Color Trail Test 
Total: 25.3% 
Gr.1: 18.1% 
Gr.2: 28.8% 
Control: 34.5% 
MedDiet + EVOO: significant 
improvement on the RAVLT 
(measures episodic declarative 
memory). 
Composite scores: 
MedDiet + EVOO: Significant 
improvement in the frontal and 
global cognition 
MedDiet +Nuts group: significant 
improvement on memory 
composite score 
MedLey 
Study by 
Knight et 
al 
Australian 
Healthy 
Older Adults 
72.0 ± 
4.94  
1 group: 
MedDiet  
 
Recorded 
nutrient 
intake 
 
High 
adherence 
rate at 90% 
Habitual 
Western diet 
0.5 137 
(70, 63) 
Comprehensive 
neurophysiological 
test battery in 5 
composites variables:  
speed of processing, 
memory, executive 
function, visual and 
special abilities, 
age-related CF  
at 0,  3,  6 months 
 
Gr.1: 17.6% 
Control: 17.3% 
No evidence of improvement of 
cognitive function among healthy 
older adults on a MedDiet 
 
Abbreviations: CDT = Clock Drawing Test, EVOO = extra virgin olive oil, MedDiet = Mediterranean diet, MMSE = Mini-Mental State Examination.  
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Table III. Summary of Findings in PREDIMED-NAVARRA Trial 
 MedDiet + EVOO 
Mean (95% CI) 
MedDiet + Nuts 
Mean (95% CI) 
Control (low fat diet) 
Mean (95% CI) 
Number of participants n=224 n=166 n=132 
MMSE 27.73 (27.27 - 28.19) 27.68 (27.20 - 28.16) 27.11 (26.61 – 27.61) 
Adjusted difference vs. control 
(95% CI) 
+0.62 (+0.18 to +1.05) +0.57 (+0.11 to +1.03) 0 (reference) 
p Value  (vs Control) 0.005 0.015  
CDT 5.31 (4.98 - 5.64) 5.13 (4.78 - 5.47) 5.31 (4.98 to 5.64) 
Adjusted difference vs. control 
(95% CI) 
+0.51 (+0.20 to +0.82) +0.33 (+0.003 to +0.67) 0 (reference) 
p Value  (vs Control) 0.001 0.048  
Abbreviations: CDT= Clock Drawing Test, CI = confidence interval, EVOO = extra virgin olive oil, MedDiet = Mediterranean diet, 
MMSE = Mini-Mental State Examination.  
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Table IV. Summary of Important Findings in Valls-Pedres et al Study 
(Baseline Cognitive Test Scores and Changes)  
Variable MedDiet + EVOO 
Mean (95% CI) 
MedDiet + Nuts 
Mean (95% CI) 
Control (low fat diet) 
Mean (95% CI) 
P-Value across 
groups 
(covariance 
adjusted) 
Number of participants n=127 n=112 n=95  
MMSE 
 
 
Baseline 
 
28.01 (27.79 to 28.24) 28.11 (27.87 - 28.35) 28.38 (28.12 to 28.65) .10 
Change 
 
0.16 (-0.12 to 0.44) -0.07 (-0.36 to 0.23) -0.26 (-0.57 to 0.06) .15 
RAVLT,  
Total 
learning 
 
Baseline 
 
39.31 (37.92 to 40.70) 39.46 (37.98 to 40.94) 39.46 (37.98 to 40.94) .98 
Change 
 
4.50 (3.24 to 5.77) a 4.26 (2.91 to 5.60) 2.10 (0.64 to 3.57) .04 
Color Trail  
 
Test, part 1b,c 
 
Baseline 
 
62.60 (56.29 to 68.91) 61.15 (53.56 to 68.74) 57.00 (49.61 to 64.38) .53 
Change 
 
-5.77 (-11.25 to -0.28) -2.44 (-5.29 to 10.26) 4.53 (-2.11 to 11.17) .045   
Color Trail  
 
Test, part 2b,c 
 
Baseline 
 
136.55 (123.19 - 149.90) 131.59 (115.13 - 148.05) 129.99 (114.39 to 145.60) .81 
Change 
 
5.66 (-10.23 to 21.55) a 24.23 (1.36 to 47.10) 37.56 (18.14 to 56.97) .045 
Summary of Significant Findings for Baseline Cognitive Functiona (Fully Covariance Adjusted Models) 
Comparisons across groups 
 
Memory Baseline 
 
0.02 (-0.11 to 0.15) 0.013 (-0.13 to 0.16) -0.04 (-0.20 to -0.11) .82 
Change 
 
0.04 (-0.09 to 0.18) 0.09 (-0.05 to 0.23) a -0.17 (-0.32 to -0.01) .04 
Frontal Baseline -0.06 (-0.25 to 0.13) 0.04 (-0.02 to 0.27) 0.12 (-0.11 to -0.34) .50 
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Cognition  
Change 
 
0.23 (0.03 to 0.43) a 0.03 (-0.25 to 0.31) -0.33 (-0.57 to -0.99) .0.03 
Global 
Cognition 
Baseline 
 
-0.07 (-0.17 to 0.04) -0.05 (-0.16 to 0.06) -0.07 (-0.19 to 0.05) .97 
Change 
 
0.05 (-0.11 to 0.21) a -0.05 (-0.27 to 0.18) 0.38 (-0.57 to -0.18) .005 
a Results are significantly different from the control group (Bonferroni post hoc test) 
b Lower values indicate improvement 
c Values measured in different number of participants (41, 25, and 30) 
Abbreviations: CDT= Clock Drawing Test, CI = confidence interval, EVOO = extra virgin olive oil, MedDiet = Mediterranean 
diet, MMSE = Mini-Mental State Examination, RAVLT = Rey Auditory Verbal Learning Test 
 
 
Table V. Summary of Primary Outcome Findings in MedLey Study 
Multivariable-Adjusted Mean Differenced in MedDiet in comparison to Control (Habitual Western Diet) 
Cognitive Function composite  Adjusted Difference  
vs Control  
95% CI P-Value vs. Control 
Total age related cognitive function +8.00 (-4.00-19.9) 0.19 
Executive function +2.53 (-2.58-7.65) 0.33 
Memory +2.00 (-3.88-7.88) 0.50 
Speed of Processing +3.24 (-1.21-7.70) 0.15 
Visual-special +0.21 (-0.38-0.81) 0.48 
Abbreviations: CI = confidence interval, MedDiet = Mediterranean diet 
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